Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi

Jaguar has received the initial $16M payment related to the company's recently executed US out-license agreement for ...
Yahoo Finance

Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal ...

Many intestinal failure patients require PS up to 7 days a week, and sometimes for 20 hours or more per day. While crucial for intestinal failure patients, PS is associated with significant toxicities ...
Cochrane

What are the benefits and risks of oils given by mouth (enteral lipids) in infants who either have or are at risk of liver disease due to intestinal failure?

There were no studies that specifically studied the effect of enteral lipids in infants at risk of liver disease or who have liver disease due to prolonged need for artificial nutrition secondary to ...
BBC

Intestinal failure patients to get faster treatment

Patients with severe intestinal failure will receive quicker treatment, following the opening of a new specialist unit at a hospital. The unit, at University Hospital, Coventry, is staffed by ...
Yahoo Finance

Jaguar Health Provides Recap of November 8, 2025 Presentation on Groundbreaking Results of Proof-of-Concept Study of Crofelemer for Treatment of Pediatric Intestinal Failure at ...

SAN FRANCISCO, CA / ACCESS Newswire / November 13, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today provided a recap of the November 8, 2025 ...
PharmiWeb

Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones

This new IP supports crofelemer's global exclusivity in rare pediatric intestinal failure coincident with published clinical data showing reductions in parenteral support requirements with crofelemer ...
Pharmabiz

Jaguar Health begins patient dosing in short bowel syndrome with intestinal failure in investigator-initiated trial of crofelemer

Jaguar Health, Inc. family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics announced that the first short bowel syndrome with intestinal failure (SBS-IF) patient has been dosed in the ...